Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia

European Journal of Clinical Pharmacology

Volumn 63, Issue 10, 2007, Pages 913-916

  Andren L ^a   Andreasson, A ^b   Eggertsen, R ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Atorvastatin; Hypericum perforatum; Interaction; LDL cholesterol; St. John's wort

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MOVINA; MULTIVITAMIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TABLET; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; FEMALE; HEPTANOIC ACIDS; HERB-DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERICUM; INTESTINES; LIVER; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PLANT PREPARATIONS; PYRROLES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UP-REGULATION;

EID: 34548577303     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0345-x     Document Type: Article

References (15)

1. Thomas KJ, Nicholl JP, Coleman P (2001) Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med 9:2-11
2. Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G (2004) BMJ 329:27-30
3. Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S (2002) Decreased plasma levels of amitriptyline and its metabolites on co- medication with an extract from St. John's wort ( Hypericum perforatum). J Clin Psychopharmacol 22:46-54
4. Piscitteli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) Indinavir concentrations and St. John's wort. Lancet 355:547-548
5. Ruschizka F, Meier PJ, Turina M, Luscher TF, Noll G (2000) Acute heart transplant rejection due to Saint John's wort. Lancet 355:548-549
6. LUPP. Läkemedelsupplysningen i Västra Sverige (lupp.su@vgregion.se)
7. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert H, Meier PJ, Fattinger K (2000) St. John's wort induces intestinal P-glucoprotein/MDR1 and intestinal and hepatic CYP 3A4. Clinical Pharmacology and Therapeutics 68:598-604
8. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD (2003) Effects of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290(11):1500-1504
9. Sugimoto KI, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada KI, Arakawa M, Sakamoto KI, Masada M, Miyamori I, Fujimura A (2001) Different effects of St. John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70(6):518-524
10. Holtzman CW, Wiggins BS, Spinler SA (2006) Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26(11):1601-1607
11. Shitara Y, Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3- hydroxy-3- methylglutaryl coenzyme A (HMG- CoA) reductase inhibitors: drug- drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112(1):71-105
12. Sever PS, Dahlöf B, Poulter NR, Wedel H et.al (2004) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower- than- average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial. The Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Drugs 64(2):43-60
13. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG et.al for the REVERSAL Investigators (2004) Effect of intensive compared with moderate lipid- lowering therapy on prognosis of coronary atherosclerosis. A randomized controlled trial. JAMA 291(9):1071-1080
14. LaRosa JC, Grundy SM, Waters DD, Shear C et.al For the Treating to New Target (TNT) Investigators (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 352(14):1425-1435
15. Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) (2002) JAMA 288:2998-3007